The EFF Spring Virtual Summit was a virtual meeting featuring the latest data from the ProQR QR-421a Stellar study, a phase 1b/2 study in USH2A mediated syndrome and retinitis pigmentosa, as well as a panel discussion with expert perspectives from the clinical and patient community.
Many thanks to Dr. Paul Yang, Krista Vasi and Mani Iyer who participated in the discussions and answered all questions from the audience.
Presented by: Daniel de Boer, CEO, ProQR Therapeutics
Time: 17:00 CET / 11:00 EST
Daniel opened the EFF Spring Virtual Summit.
Presented by: Aniz Girach, Chief Medical Officer, ProQR Therapeutics
Time: 17:05 CET / 11:05 EST
Aniz presented a short update on the status of the ProQR Usher syndrome program, including the outcome from the recent clinical milestone.
For a more detailed presentation on the recent Stellar clinical trial results of the QR-421a program for USH2A mediated Usher syndrome and retinitis pigmentosa, please watch (listen to) the video below.
On our YouTube channel you can navigate through the video using the timestamp links in the description.
Dr. Paul Yang, Krista Vasi and Mani Iyer were invited to the panel discussion on Usher syndrome clinical trials and the IRD community to answer all the questions the audience may have. What is the current state of clinical research in Usher syndrome? What is the patients’ perspective on current clinical research?
Speaker: Jennifer Pluim
Time: 18:25 CET / 12:25 EST
If you would like to receive updated on future events, please subscribe.